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Abstract: The concomitant use of non-selective S-(2-boron-ethyl)-L-cysteine (BEC) arginase 
inhibitor with simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the 
background of endotoxin-induced disorder modeling by Staphylococcus aureus (strain 13407) 
injection under the skin – 60 billions of microbial bodies – exhibits an endothelium- and cardio-
protective action which is evident as endothelial dysfunction factor (EDF) increase prevention, 
adrenoreactivity, maintenance of myocardial reserve, and normalization of biochemical markers 
(total NO, expression of eNOS, C-reactive protein, IL-6, tumor necrosis factor). However, the 
concomitant therapy has shown no additive action of medications. 
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Introduction: Great attention has been recently 
paid to endotoxin-induced cardiovascular injuries in 
abdominal surgery [1, 2, 3, 4]. In this respect, a clear 
sequence of events has been arranged: endotoxin 
shock with a multisystem disorder, -> release of 
proinflammatory cytokines, -> endothelial dysfunction 
->, systemic vasculitis ->, vascular and endothelium 
permeability increase for lymphocytes ->, 
hyperlipoproteinemia ->, start of an atherosclerotic 
process [1, 2, 3, 4, 5, 6]. 
Under that logic, a similar algorithm could be 
used for any endotoxin-induced disorder regardless 
its cause considering critically high levels of 
proinflammatory cytokines [5, 6]. 
It is likely that concomitant use of HMG-CoA 
reductase inhibitors and arginase inhibitors is one of the 
pharmacological strategies to correct an endotoxin-
induced endothelial dysfunction [7, 8, 9, 10]. 
Methods: tests have been run with white male 
Wistar rats weighing 200 to 250 grams. When creating 
a model of the endotoxin-induced endothelial 
dysfunction (EIED), the rats have been infected with 
Staphylococcus aureus (strain 13407) under the skin – 
60 billions of microbial bodies – succeeded (in 24 
hours) by sensibilization of the laboratory animal 
(0.1ml of staphylococcal anatoxin under the skin) 
followed by generalization of the infectious agent with 
a daily massage of the injection site. Then, a 
compression and pneumatic massage of the injection 
site was made daily within 10 minutes. 
HMG-CoA reductase inhibitors in combination 
with an S-(2-boron-ethyl)-L-cysteine (BEC) arginase 
inhibitor (WIRUD GmgH, Hamburg) – 10mg/kg – 
have been daily injected intragastrically within 7 
days. The animals have been divided into 
experimental groups (n = 10): 1 – intact ones; 2 – 
endotoxin-induced endothelial dysfunction (EIED); 3 – 
EIED + BEC 10mg/kg; 4 – EIED + simvastatin 
8.5mg/kg; 5 – EIED + atorvastatin 4.3mg/kg; 6 – 
EIED + rosuvastatin 8.5mg/kg; 7 – EIED + 
nanaparticulated rosuvastatin 11.6mg/kg; 8 – EIED + 
simvastatin 8.5mg/kg + BEC 10mg/kg; 9 – EIED + 
atorvastatin 4.3mg/kg + BEC 10mg/kg; 10 – EIED + 
rosuvastatin 8.5mg/kg + BEC 10mg/kg; 11 – EIED + 
nanaparticulated rosuvastatin 11.6mg/kg + BEC 
10mg/kg. 
On the eighth day since the beginning of the test, 
the animals were catheterized into the left carotid 
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artery under anesthesia (300 mg/kg chloral hydrate) 
to register blood pressure (BP); the bolus dose of 
pharmacological agents has been injected into the 
femoral vein. Hemodynamic parameters: systolic 
blood pressure (SBP), diastolic blood pressure 
(DBP) and heart rate (HR) have been measured 
constantly with the Biopac hardware and software 
system. Beside BP measuring, several functional 
tests have been run in the following sequence: 1. 
Test on endothelium-dependent vascular relaxation 
(intravenous injection of acetyl choline (ACh) 
solution dosing 40 mkg/kg at the rate of 0.1ml 
per 100g). 2. Test on endothelium-independent 
vascular relaxation (intravenous injection of 
sodium nitroprusside (SNP) solution dosing 
30 mkg/kg at the rate of 0.1ml per 100g) [11, 12, 
13, 14]. 
The experimental animals’ endothelial 
dysfunction extent as well as level of dysfunction 
correction with the medications tested have been 
assessed according to the estimated factor of 
endothelial dysfunction (EDF) [11, 12, 13, 14]. 
To assess the cardioprotective activity, 
functional tests on adrenoreactivity [11, 12, 13, 14] 
and myocardial reserve exhaustion [11, 12, 13, 14] 
have been run. 
The dynamics of biochemical markers (total 
NO, expression of eNOS, C-reactive protein, IL-6, 
tumor necrosis factor) of the animals with 
endotoxin-induced endothelial dysfunction have 
been assessed with standard reagent kits [11, 12, 
13, 14]. 
Accuracy of changes in absolute values has 
been defined by the difference method of the 
variation statistics with finding the mean shifts 
(M), the arithmetical mean (±m), and error 
probability (p) using Student’s t-distribution tables. 
Differences have been assessed as accurate at 
p<0.05. Statistical data have been calculated with 
Microsoft Excel 7.0. 
Results: Daily intragastric monotherapy of 
non-selective L-norvaline arginase inhibitor 
(10mg/kg) on the background of modeling a sepsis-
induced endothelial dysfunction has moderately 
normalized the EDF and had no remarkable 
influence on BP values (Table 1). The EDF was 
2.5±0.4 units. HMG-CoA reductase inhibitors – 
simvastatin (8.5mg/kg), atorvastatin (4.3mg/kg), 
rosuvastatin (8.5mg/kg), and nanoparticulated 
rosuvastatin (11.6mg/kg) – in the most efficient 
doses, have significantly improved the EDF and 
had no effect on the BP (Table 1). The EDF values 
were in the range of 2.3 to 1.5 units. 
The concomitant use of BEC with statins has 
shown no additive effect on the EDF and BP. The 
values have been even a bit higher than in case of 
the statin monotherapy though they have 
remarkably differed from the intact animals in 
statistics (Table 1). 
At the same time, a positive dynamics of the 
indices of contractility has been revealed when 
running EKG stress tests in animals with sepsis-
induced endothelial dysfunction (Table 2). Activity 
of BEC was second to statins both regarding 
prevention of adrenoactivity increase and 
maintenance of dilatation reserve. The concomitant 
use of BEC with simvastatin, atorvastatin, 
rosuvastatin, and nanoparticulated rosuvastatin has 
resulted in no additive enhancement while chamber 
pressure parameters, in case of EKG stress tests, 
have approached additive enhancement in the BEC 
series and have been behind HMG-CoA reductase 
inhibitors (Table 2). 
A similar trend has been found out regarding 
parameters of biochemical markers of the animals 
with sepsis-induced endothelial dysfunction 
(Table 3). 
The most significant protective action of the 
concomitant use of BEC with HMG-CoA reductase 
inhibitors - simvastatin, atorvastatin, rosuvastatin, 
and nanoparticulated rosuvastatin – has been 
evident regarding the level of C-reactive protein 
and values of proinflammatory cytokines IL-6 and 
tumor necrosis factor with their levels being 
comparable in any experiment series with 
pharmacotherapy. We have not seen additive action 
of the concomitant use for this model of disorders 
(Table 3). 
Conclusion: The concomitant use of non-
selective BEC arginase inhibitor with simvastatin, 
atorvastatin, rosuvastatin and nanoparticulated 
rosuvastatin on the background of sepsis-induced 
disorder modeling by Staphylococcus aureus 
(strain 13407) injection under the skin – 60 billions 
of microbial bodies – exhibits an endothelium- and 
cardio-protective action which is evident as EDF 
increase prevention, adrenoreactivity, maintenance 
of myocardial reserve, and normalization of 
biochemical markers (total NO, expression of 
eNOS, C-reactive protein, IL-6, tumor necrosis 
factor). However, the concomitant therapy has 
shown no additive action of medications. 
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Table 1 
Influence of the concomitant use of non-selective BEC arginase inhibitor with simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin  
on dynamics of hemodynamic parameters of animals with endotoxin-induced endothelial dysfunction (М±м, n=10) 
Group of Animals SBP DBP EDF 
Intact 129.4±2.2 89.2± 1.1 1.1 ± 0.1
Endotoxin-Induced Endothelial Dysfunction (EIED) (n=10) 117.6±2.3* 85.0±2.1 3.7±0.5* 
EIED + BEC 10mg/kg (n=10) 115.3±2.4 79.1±2.2 2.5±0.4* 
EIED + Simvastatin 8.5mg/kg (n=10) 127.3±2.8 87.1±1.9 2.3±0.5*# 
EIED + Atorvastatin 4.3mg/kg(n=10) 130.0±3.3 85.8±2.2 2.1±0.3*# 
EIED + Rosuvastatin 8.5mg/kg (n=1) 135.0±3.8 83.1±2.1 1.7±0.5*# 
EIED + Nanoparticulated Rosuvastatin 11.6mg/kg (n=10) 129.6±4.3 84.9±2.0 1.5±0.2*# 
EIED + BEC 10mg/kg + Simvastatin 8.5mg/kg (n=10) 122.1±3.0 84.1±2.1 2.6±0.4* 
EIED + BEC 10mg/kg + Atorvastatin 4.3 mg/kg(n=10) 125.3±3.2 82.3±2.0 2.5±0.3* 
EIED + BEC 10mg/kg + Rosuvastatin 8.5mg/kg (n=1) 126.3±3.1 81.9±2.1 2.7±0.4* 
EIED + BEC 10mg/kg + Nanoparticulated Rosuvastatin 11.6mg/kg (n=10) 127.3±3.2 84.2±2.4 2.5±0.3* 
Note: SBP – systolic blood pressure (mmHg), DBP – diastolic blood pressure (mmHg), EDF – endothelial dysfunction factor (units), * – accurate difference with the 
group of intact animals (р<0.05); # – accurate difference with the group of endotoxin-induced endothelial dysfunction (EIED) (р<0.05). 
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Table 2 
Influence of the concomitant use of non-selective BEC arginase inhibitor with simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin  
on dynamics of indices of contractility in case of EKG stress tests in animals with endotoxin-induced endothelial dysfunction (М±м, n=10). 
Group of Animals Adrenoreactivity 
(mmHg) 
Myocardial Reserve 
Exhaustion (%) 
Intact 201.5±9.4 112.7±10.9 
Endotoxin-Induced Endothelial Dysfunction (EIED) (n=10) 240.3±8.7* 79.4±3.9* 
EIED + BEC 10mg/kg (n=10) 220.7±8.3* 92.4±5.7* 
EIED + Simvastatin 8.5mg/kg (n=10) 232.0±8.9* 87.4±3.7* 
EIED + Atorvastatin 4.3mg/kg(n=10) 222.1±8.5*# 97.0±4.9* 
EIED + Rosuvastatin 8.5mg/kg (n=1) 221.0±8.4*# 109.4±5.7*# 
EIED + Nanoparticulated Rosuvastatin 11.6mg/kg (n=10) 219.1±8.7*# 99.9±6.3*# 
EIED + BEC 10mg/kg + Simvastatin 8.5mg/kg (n=10) 232.6±7.5*# 89.1±3.6*# 
EIED + BEC 10mg/kg + Atorvastatin 4.3 mg/kg(n=10) 231.9±8.4*# 88.9±3.9*# 
EIED + BEC 10mg/kg + Rosuvastatin 8.5mg/kg (n=1) 223.9±9.6*# 88.5±4.9*# 
EIED + BEC 10mg/kg + Nanoparticulated Rosuvastatin 11.6mg/kg (n=10) 226.5±8.4*# 90.1±5.0*# 
Note: * – accurate difference with the group of intact animals (р<0.05); # – accurate difference with the group of endotoxin-induced endothelial dysfunction (EIED) 
(р<0.05). 
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Table 3 
Influence of the concomitant use of non-selective BEC arginase inhibitor with simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin  
on value dynamics of biochemical markers (total NO, expression of eNOS, C-reactive protein, IL-6, tumor necrosis factor) 
of animals with endotoxin-induced endothelial dysfunction (М±м, n=10). 
Group of Animals NOх 
Expression of 
еNOS 
CRP Level IL-6 TNF 
Intact 116.8±10.3 5.4±0.21 0.05±0.01 0.43±0.17 8.42±2.51 
Endotoxin-Induced Endothelial Dysfunction (EIED) (n=10) 182.3±12.4* 0.04±0.01* 0.38±0.01* 6.87±1.93* 17.83±3.79* 
EIED + BEC 10mg/kg (n=10) 141.4±12.7*# 1.97±0.10*# 0.21±0.02*# 2.78±1.79*# 10.23±2.08*# 
EIED + Simvastatin 8.5mg/kg (n=10) 122.9±8.4*# 1.93±0.12*# 0.08±0.01*# 1.03±0.62*# 10.76±1.70*# 
EIED + Atorvastatin 4.3mg/kg(n=10) 130.0±10.9*# 2.07±0.21*# 0.09±0.01*# 1.27±0.33*# 9.89±1.79*# 
EIED + Rosuvastatin 8.5mg/kg (n=1) 122.1±9.9#* 3.04±0.35*# 0.11±0.01*# 1.17±0.33*# 10.80±1.99*# 
EIED + Nanoparticulated Rosuvastatin 11.6mg/kg (n=10) 132.1±10.3*# 4.01±0.56*# 0.18±0.01*# 1.48±0.24*# 9.56±1.87*# 
EIED + BEC 10mg/kg + Simvastatin 8.5mg/kg (n=10) 145.7±10.7*# 2.19±0.37*# 0.38±0.06*# 2.54±0.24*# 9.12±1.12*# 
EIED + BEC 10mg/kg + Atorvastatin 4.3 mg/kg(n=10) 143.5±9.9*# 2.41±0.34*# 0.42±0.08*# 1.94±0.19*# 8.79±0.91*# 
EIED + BEC 10mg/kg + Rosuvastatin 8.5mg/kg (n=1) 139.1±9.5*# 2.52±0.41*# 0.57±0.09*# 1.89±0.21*# 8.42±0.87*# 
EIED + BEC 10mg/kg + Nanoparticulated Rosuvastatin 11.6mg/kg 
(n=10) 
117.8±10.0*# 2.97±0.41*# 0.83±0.09*# 1.87±0.20*# 7.56±0.79*# 
Note: NOx – terminal metabolites NO (µmol/l); Expression of еNOS (%);CRP Level – level of C-reactive protein (mg/l); IL-6 – interleukin-6 (pg/mL); TNF – tumor 
necrosis factor (pg/mL), * – accurate difference with the group of intact animals (р<0.05); # – accurate difference with the group of endotoxin-induced endothelial 
dysfunction (EIED) (р<0.05). 
1(1): 3-8., №Vol. 1endothelial dysfunction. Research result: pharmacology and clinical pharmacology. 2015.
-boron-ethyl)-L-cysteine arginase inhibitor to correct endotoxin-induced 2-(Denisiuk T.A., Demchenko S.A., Saroyan K.V. Сoncomitant use of statins and S
 
 
8 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
References 
1. Savel'ev V.S., Iablokov E.G., Petukhov V.A.
Lipid distress syndrome in surgery. Bulletin of 
Experimental Biology and Medicine. Vol.127, No. 6 
(1999): P. 604–611.[OpenUrl]  
2. Savel'ev V.S., Petukhov V.A., An E.S. et al.
Endothelial dysfunction in lipid distress syndrome and 
dismetabolic effects of peritonitis. Russian Medical 
Journal. Vol. 17, No.14 (2009): P. 881-890. 
[eLIBRARY] [Full text] 
3. Broekhuizena L.N., Mooija H.L., Kastelein J.J. et
al. Endothelial glycocalyx as potential diagnostic and 
therapeutic target in cardiovascular disease. Current 
Opinion in Lipidology. Vol. 20 (1) (2009): P. 57–
62. [PubMed]
4. Becker B.F., Daniel Chappell, Dirk Bruegger et
al. Therapeutic strategies targeting the endothelial 
glycocalyx: acute deficits, but great potential. Cardiovasc. 
Res. Vol. 87 (2) (2010): P. 300-310. [PubMed][Full text]  
5. Knyazeva S.G., Lazarev A.I., Rybnikov V.N. et al.
Clinical and immunological efficiency of Imunofan, 
Glutoxim and Mexidol in patients with chronic salpingo-
oophoritis in application of laparoscopic treatment methods. 
Kursk scientific and practical bulletin "Man and his health". 
No.3 (2007): P. 74-81. [eLIBRARY] [Full text] 
6. Lazareva G.A., Brovkina I.L., Prokopenko L.G.
Essentiale and riboxin as inducers of immunomodulant 
activity of erythrocyte stroma under normal conditions 
and with toxic anemia. Experimental and Clinical 
Pharmacology. Vol. 67, No.5 (2004): P. 23-27. 
[eLIBRARY] 
7. Pokrovskiy M.V., Korokin M.V., Tsepeleva S.A.
et al. Аrginase inhibitor in the pharmacological correction 
of endothelial dysfunction. International journal of 
hypertension. Vol. 2011 (2011): art. no. 
515047. [PMC][PubMed] 
8. Pokrovskii M.V., Pokrovskaya T.G., Kochkarov
V.I. et al. Endothelium protective properties of L-arginine 
on a nitric oxide deficiency model. Russian Journal of 
Experimental and Clinical Pharmacology. No. 71 (2) 
(2008): P. 29-31. [eLIBRARY] [Full text]  
9. Tsepeleva S.A., Pokrovskii M.V., Pokrovskaya
T.G. et al. Cardio- and endothelium-protective effects of 
arginase inhibitor L-norvalin at modelling L-NAME-
induced deficiency of nitric oxide. Kuban Research 
Medical Bulletin. No.4 (2011): P.185-188. [eLIBRARY] 
10. Kamada Y., Nagaretani H., Tamura S. et
al. Vascular endothelial dysfunction resulting from 
L-arginine deficiency in a patient with lysinuric protein 
intolerance. J. Clin. Invest. Vol. 108 (2001): 
P. 717-724. [PMC][PubMed]  
11. Pokrovskii M.V., Artyushkova E.B., Pokrovskaya
T.G. Methods of experimental modeling of endothelial 
dysfunction. Allergology and Immunology. Vol. 9, No. 3 
(2008): P. 327. [eLIBRARY] 
12. Gumanova N.G., Metelskaya V.A., Artyushkova
E.B., Kochkarov V.I., Pokrovskaya T.G., Danilenko L.M., 
Korneev M.M., Pokrovskii M.V., Pashin E.N. Effect of 
antioxidants Q510 and resveratrol on regulatory function 
of the endothelium in rats with modeled arterial 
hypertension. Bulletin of Experimental Biology and 
Medicine. Vol. 143, No.6 (2007): P. 619-622. 
[eLIBRARY] 
13. Korokin M.V., Nosov A.M., Pokrovskii M.V. et
al. Comparative research of endothelium- and 
cardioprotective properties of furostanole glycosides of 
Dioscorea Deltoidea cell culture and 17β-oestradiol. 
Kuban Research Medical Bulletin. No.9 (2006): 
P. 137-140. [eLIBRARY] 
14. Artyushkova E.V., Pokrovskii M.V., Artyushkova
E.B. et al. Endothelium- and cardioprotective effects of 
meldonium and trimetazidine in case of L-NAME-induced 
endothelial dysfunction in experiment. Kursk scientific 
and practical bulletin "Man and his health". 
No.3 (2010): P. 5-10. [eLIBRARY] [Full text] 
The research has been performed with support 
from the grant of RF President No. MD-4711.2015.7, grant 
of RF President No. MK-3136.2014.4 and RF Ministry of 
Education and Science (Agreement No.14.578.21.0012, 
agreement unique identifier RFMEFI57814X0012) 
Denisiuk T.A., Demchenko S.A., Saroyan K.V. Сoncomitant use of statins and S-(2-boron-ethyl)-L-
cysteine arginase inhibitor to correct endotoxin-induced endothelial dysfunction. Research result: 
pharmacology and clinical pharmacology. 2015. Vol. 1, №1(1): 3-8. 
